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of PBPC. Several European studies had demonstrated a correla- 
tion between precol lect ion CD34+ cells and the nmnber  of 
CD34+ cells collected. However, it is not standard of practice to 
measure preCD34+ counts and base decisions regarding leuka- 
pheresis procedures on these values. In order to investigate the 
most cost effective method and to minimize number of leuka- 
pheresis procedures for optimal PBPC collection, we retrospec- 
tively analyzed data from 42 patients with hematologic malignan- 
cies. Patient diagnoses included nmltiple myeloma, lymphoma nd 
leukemia. Chemotherapy  mobi l izat ion regimens included 
cyclophosphamide, ICE (ifosfamide, carboplatinum and etopo- 
side) and high dose cytarabine and etoposide. G-CSF was given at 
10mcg/kg/day. Several patients were mobilized with growth factor 
alone. Large volume apheresis procedures were done. Three main 
parameters were monitored prior to each apheresis procedure, the 
YVBC, the preCD34+ count and the CD34+ cells collected. There 
was a significant correlation between the preCD34+ count and the 
apheresis CD34+ cell yield. The study indicated that a collection 
of 2.5 X 10 E 6/kg CD34+ cells was obtained in majority of the 
patients if the preCD34+ count was >20/ul. We were unable to 
collect 2.5 X 10 E 6/kg if preCD34 counts were < 5/ul despite 
numerous leukapheresis procedures. If preCD34 counts were 
more than 75-85/ul patients were able to collect 5 X 10 E 6 
CD34+/kg cells in one large volmne procedure. We also noticed a 
weak correlation between the WBC and the preCD34+ count. A 
WBC of 5k/uI or more was noted in most patients who had 
preCD34+ cells of > 10/ul. From our study, we proposed the most 
cost effective method to find the optimal timing for starting PBPC 
collections is to monitor initially with WBC until the count is 
5k/ul. Subsequently, preCD34+ cell count should be used for con- 
tinued monitoring. Leukapheresis i initiated when preCD34+ 
count are > 20/ul in order to collect sufficient CD34+ cells. 
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AUTOLOGOUS BLOOD AND MARROW TRANSPLANTATION (BMT) IN 
OLDER ADULTS (60 YEARS AND OLDER) 
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From April 1994 to July 2002 we performed autologous BMT 
on 82 patients 60 years of age and older for a variety of condi- 
tions. Thirty-six males and 46 females with a median age of 63 
(range 60 to 74) were given a total of 100 transplants. Indica- 
tions for transplant included lymphoma (26), multiple myeloma 
(22), breast cancer (20), acute myelogenous leukemia (7), amy 
loidosis (5), and Hodgkin's disease (2). A variety of preparative 
regimens were employed as shown below. One patient received 
marrow plus peripheral  blood stem cells (PBSC), while 81 
received PBSC only. Priming for mobilization of PBSC includ- 
ed CY plus G CSF and GM-CSF (51), G-CSF alone (20), CY 
plus G-CSF  (I2), VP16 plus G-CSF  (2), and rebound from 
CHOP (i). The median nmnber of days to collect the target 
PBSC was 2 (range 1 to 7). Four patients had to be remobilized 
due to insufficient collection on the first attempt, while 37 
patients required only one day of collection to reach the target. 
A median of 5.21 x i0C'/kg CD34 positive cells (range 1.42 to 
40.57) and 3.80 x 106/kg CD34 positive cells (range 1.40 to 
40.57) were collected and infused, respectively. All patients had 
leukocyte recovery with a median time to ANC > 500 of 10 days 
(range 8 to 16). Recovery of platelets > 50 occurred in 93 trans- 
plants at a median of 18 days (range 12 to 259); in seven trans- 
plants (six pts; three AML, three lymphoma) platelet recovery to 
> 50 did not occur. Fifty-one of 77 evaluable patients (66%) 
achieved a complete response after transplant. Overall survival 
and disease free survival at three years is 44.6% (95% CI 31.6- 
57.6) and 24.2% (95% C1 13.9-34.5), respectively. Forty-five 
patients are alive and only two deaths were attributed to toxici- 
ties related to autologous transplant (VOD - one pt, ARDS - 
one pt). Our experience with transplantation i this group of 
patients has been favorable and no upper age limit has been 
identified. 
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NOVEL HIGH DOSE CHEMOTHERAPY REGIMEN FOR AUTOLOGOUS 
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High dose chemotherapy (HDCT)  followed by autologous 
hematopoietic stem cell (HSC) rescue is an accepted treatment for 
relapsed or refractory Hodgkin's Disease (HD). Many patients 
with HD have had prior radiation therapy which precludes the use 
of total body" irradiation (TBI) in the preparative regimen. Multi- 
ple HDCT regimens without TBI have been used, most common- 
ly CBV and BEAM, with reported overall survival (OS) and dis- 
ease free survival (DFS) rates ranging from 30 to 68% and 25 to 
50%, respectively, depending on length of follow-up and disease 
status (chemosensitive or chemorefractory) at transplant. The 
most commonly reported regimen-related to,c i ty (RRT) is inter- 
stitial pneumonitis related to carmustine. At the University of 
Wisconsin Hospital and Clinics (U~VHC) a novel HDCT regi- 
men of thiotepa nd etoposide was developed for use in HD and 
Non-Hodgkin's Lymphoma and consists of thiotepa 300rag/m2 
and etoposide 700rag/m2 given consecutively on days -6, -5, and - 
4. Since 1987, f i fty-three patients with HD have undergone 
HDCT and autologous HSC rescue utilizing this reginren. Medi- 
an age was 33 years, and the majority of patients (89%) had nodu- 
lar sclerosing HD. At the time of transplant 9 (I7%) patients were 
in complete remission, 30 (57%) patients were in partial remis- 
sion, and 11 (21%) patients were refractory to salvage therapy. 
Eight ( i5%) were considered primary induction failures, and 6 
(11%) were in second or third relapse. Three patients were in 
untreated relapse. Response to induction therapy was < I2 months 
in 32 (60%) patients. With a median follow-up of 45.7 months, 
five year OS is 59% (95%CI, 35-82%), and DFS is 36% (95%CI, 
4-67%). The most common RRT was reversible gastrointestinal 
toxicity. Grade III stomatitis occurred in 60%. There was no 
grade IV stomatitis. Other grade III toxicities included febrile 
neutropenia (98%), thrombosis (7%), and electrolyte abnormali- 
ties (16.7%). One patient died before day +100 due to progressive 
HD, but there were no deaths due to RRT. Two patients have 
developed secondary myelodysplasia. No cases of interstitial pneu- 
monitis occurred, and no patients developed VOD. In conclusion, 
thiotepa and etoposide is a novel HDCT regimen for use in 
patients with relapsed or refractory HD which offers low RRT 
and equivalent long-term OS and DFS compared to other report- 
ed HDCT regimens. 
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Background: Variable r sults with autologous and allogeneic 
stem cell transplantation for mantle ceil lymphoma have been 
reported by single institutions. Methods: We analyzed ata on 23 
patients who underwent a total of 24 peripheral blood stem cell 
and bone marrow transplants at Vanderbilt University Hospital 
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